drugset / Trial / NCT00418639

Study of Nitazoxanide in the Treatment of Chronic Hepatitis C

NCT00418639

Phase 2 Completed 50 enrolled Romark Laboratories L.C.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the effect of treatment with 24 weeks nitazoxanide monotherapy on end of treatment virologic response, sustained virologic response, reduction of quantitative serum HCV RNA, changes in ALT and safety parameters.

Timeline

Start
2005-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitazoxanide Other / unclassified